Literature DB >> 26069061

Overexpression Models: Lentiviral Modeling of Brain Cancer.

Dinorah Friedmann-Morvinski1, Oded Singer1.   

Abstract

Glioblastoma multiforme (GBM) is one of the most common and most malignant of the brain tumors. Gliomas can be classified into four different grades according to their histologic characteristics; the most aggressive of the gliomas is glioblastoma multiforme (grade IV). Despite optimal treatment, the median survival is only 12 to 15 months. In the past few years, important advances were made in understanding the biology and pathology of malignant gliomas. A mouse model of brain tumors using inducible lentiviral vectors is described here. In this approach, a lenti-vector with loxP sites flanking the gene of interest (oncogene) is injected into mice expressing Cre recombinase under the control of a brain-specific promoter. The steps to perform cell-type/region-specific injection of Cre-loxP-controlled lentiviral vectors in the brain of adult mice are described here in detail. Curr. Protoc. Mouse Biol. 3:121-139 © 2013 by John Wiley & Sons, Inc.
Copyright © 2013 John Wiley & Sons, Inc.

Entities:  

Keywords:  Cre-loxP system; gene delivery; genetic alterations; gliomas; lentivirus gene transfer

Year:  2013        PMID: 26069061     DOI: 10.1002/9780470942390.mo110271

Source DB:  PubMed          Journal:  Curr Protoc Mouse Biol        ISSN: 2161-2617


  2 in total

1.  Phenotypic characterization with somatic genome editing and gene transfer reveals the diverse oncogenicity of ependymoma fusion genes.

Authors:  Mutsumi Takadera; Kaishi Satomi; Frank Szulzewsky; Patrick J Cimino; Eric C Holland; Tetsuya Yamamoto; Koichi Ichimura; Tatsuya Ozawa
Journal:  Acta Neuropathol Commun       Date:  2020-11-23       Impact factor: 7.801

2.  Isolation and characterization of the immune cell fraction from murine brain tumor microenvironment.

Authors:  Ignacio Mastandrea; Divsha Sher; Prerna Magod; Dinorah Friedmann-Morvinski
Journal:  STAR Protoc       Date:  2022-01-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.